Skip to main content
Top
Published in: Journal of Ovarian Research 1/2018

Open Access 01-12-2018 | Research

Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?

Authors: Hanifi Sahin, Mehmet Mutlu Meydanli, Mustafa Erkan Sari, Ibrahim Yalcin, Gonca Çoban, Nazlı Topfedaisi Ozkan, Zeliha Firat Cuylan, Baki Erdem, Kemal Gungorduk, Özgür Akbayir, Murat Dede, Mustafa Coşkun Salman, Tayfun Güngör, Ali Ayhan

Published in: Journal of Ovarian Research | Issue 1/2018

Login to get access

Abstract

Background

The purpose of this retrospective study was to determine the prognosis of non-serous epithelial ovarian cancer (EOC) patients with exclusively retroperitoneal lymph node (LN) metastases, and to compare the prognosis of these women to that of patients who had abdominal peritoneal involvement.

Methods

A multicenter, retrospective department database review was performed to identify patients with stage III non-serous EOC at 7 gynecologic oncology centers in Turkey. Demographic, clinicopathological and survival data were collected. The patients were divided into three groups based on the initial sites of disease: 1) the retroperitoneal (RP) group included patients who had positive pelvic and /or para-aortic LNs only. 2) The intraperitoneal (IP) group included patients with > 2 cm IP dissemination outside of the pelvis. These patients all had a negative LN status, 3) The IP / RP group included patients with > 2 cm IP dissemination outside of the pelvis as well as positive LN status. Survival data were compared with regard to the groups.

Results

We identified 179 women with stage III non-serous EOC who were treated at 7 participating centers during the study period. The median age of the patients was 53 years, and the median duration of follow-up was 39 months. There were 35 (19.6%) patients in the RP group, 72 (40.2%) in the IP group and 72 (40.2%) in the IP/RP group. The 5-year disease-free survival (DFS) rates for the RP, the IP, and IP/RP groups were 66.4%, 37.6%, and 25.5%, respectively (p = 0.002). The 5-year overall survival (OS) rate for the RP group was significantly longer when compared to those of the IP, and the IP/RP groups (74.4% vs. 54%, and 36%, respectively; p = 0.011). However, we were not able to define “RP only disease” as an independent prognostic factor for increased DFS or OS.

Conclusions

Primary non-serous EOC patients with node-positive-only disease seem to have better survival when compared to those with extra-pelvic peritoneal involvement.
Literature
1.
go back to reference Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer. 2009;19 Suppl 2:S18–20.CrossRefPubMed Berek JS. Lymph node-positive stage IIIC ovarian cancer: a separate entity? Int J Gynecol Cancer. 2009;19 Suppl 2:S18–20.CrossRefPubMed
2.
go back to reference Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, Velipasaoglu M, Yuce K. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? Gynecol Oncol. 2008;108:428–32.CrossRefPubMed Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S, Velipasaoglu M, Yuce K. Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? Gynecol Oncol. 2008;108:428–32.CrossRefPubMed
3.
go back to reference Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, Matsumoto K, Taketani Y. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer. 1998;83:1555–60.CrossRefPubMed Onda T, Yoshikawa H, Yasugi T, Mishima M, Nakagawa S, Yamada M, Matsumoto K, Taketani Y. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenctomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer. 1998;83:1555–60.CrossRefPubMed
4.
go back to reference Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol. 1999;73:237–41.CrossRefPubMed Kanazawa K, Suzuki T, Tokashiki M. The validity and significance of substage IIIC by node involvement in epithelial ovarian cancer: impact of nodal metastasis on patient survival. Gynecol Oncol. 1999;73:237–41.CrossRefPubMed
5.
go back to reference Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol. 2006;103:797–801.CrossRefPubMed Cliby WA, Aletti GD, Wilson TO, Podratz KC. Is it justified to classify patients to stage IIIC epithelial ovarian cancer based on nodal involvement only? Gynecol Oncol. 2006;103:797–801.CrossRefPubMed
6.
go back to reference Ferrandina G, Scambia G, Legge F, Petrillo M, Salutari V. Ovarian cancer patients with “node-positive-only” stage IIIC disease have a more favorable outcome than stage IIIA/B. Gynecol Oncol. 2007;107:154–6.CrossRefPubMed Ferrandina G, Scambia G, Legge F, Petrillo M, Salutari V. Ovarian cancer patients with “node-positive-only” stage IIIC disease have a more favorable outcome than stage IIIA/B. Gynecol Oncol. 2007;107:154–6.CrossRefPubMed
7.
go back to reference Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol. 2008;19:223–8.CrossRefPubMedPubMedCentral Baek SJ, Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. J Gynecol Oncol. 2008;19:223–8.CrossRefPubMedPubMedCentral
8.
go back to reference Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. Int J Gynecol Pathol. 2014;33:302–8.CrossRefPubMed Bakkar R, Gershenson D, Fox P, Vu K, Zenali M, Silva E. Stage IIIC ovarian/peritoneal serous carcinoma: a heterogeneous group of patients with different prognoses. Int J Gynecol Pathol. 2014;33:302–8.CrossRefPubMed
9.
go back to reference Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a gynecologic oncology group study. Gynecol Oncol. 2012;124:53–8.CrossRefPubMed Rungruang B, Miller A, Richard SD, Hamilton CA, Rodriguez N, Bookman MA, Maxwell GL, Krivak TC, Horowitz NS. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a gynecologic oncology group study. Gynecol Oncol. 2012;124:53–8.CrossRefPubMed
10.
go back to reference Suh DH, Kim TH, Kim JW, Kim SY, Kim HS, Lee TS, Chung HH, Kim YB, Park NH, Song YS. Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture. J Gynecol Oncol. 2013;24:352–8.CrossRefPubMedPubMedCentral Suh DH, Kim TH, Kim JW, Kim SY, Kim HS, Lee TS, Chung HH, Kim YB, Park NH, Song YS. Improvements to the FIGO staging for ovarian cancer: reconsideration of lymphatic spread and intraoperative tumor rupture. J Gynecol Oncol. 2013;24:352–8.CrossRefPubMedPubMedCentral
11.
go back to reference Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.CrossRefPubMed Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch. 2012;460:237–49.CrossRefPubMed
12.
go back to reference Kurman RJ, Carcangui ML, Herrington CS, Young RH. Tumors of the ovary, WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014. p. 11–4. Kurman RJ, Carcangui ML, Herrington CS, Young RH. Tumors of the ovary, WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IARC; 2014. p. 11–4.
13.
go back to reference Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and Para-aortic lymphadenectomy in cancer of the ovary. Baillieres Clin Obstet Gynaecol. 1989;3:131–42.CrossRefPubMed Di Re F, Fontanelli R, Raspagliesi F, Di Re E. Pelvic and Para-aortic lymphadenectomy in cancer of the ovary. Baillieres Clin Obstet Gynaecol. 1989;3:131–42.CrossRefPubMed
14.
go back to reference Petru E, Lahousen M, Tamussino K, Pickel H, Stranzl H, Stettner H, Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170:656–62.CrossRefPubMed Petru E, Lahousen M, Tamussino K, Pickel H, Stranzl H, Stettner H, Winter R. Lymphadenectomy in stage I ovarian cancer. Am J Obstet Gynecol. 1994;170:656–62.CrossRefPubMed
15.
go back to reference Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.CrossRefPubMed Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88:2584–9.CrossRefPubMed
16.
go back to reference Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol. 1991;9:1138–50.CrossRefPubMed Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, Park RC. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the gynecologic oncology group experience. J Clin Oncol. 1991;9:1138–50.CrossRefPubMed
17.
go back to reference Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–25.CrossRefPubMedPubMedCentral Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719–25.CrossRefPubMedPubMedCentral
18.
go back to reference Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRefPubMed Prat J, Oncology FCoG. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRefPubMed
19.
go back to reference Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122:536–40.CrossRefPubMed Powless CA, Aletti GD, Bakkum-Gamez JN, Cliby WA. Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011;122:536–40.CrossRefPubMed
20.
go back to reference Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401–4.CrossRefPubMed Mutch DG, Prat J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol Oncol. 2014;133:401–4.CrossRefPubMed
Metadata
Title
Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Authors
Hanifi Sahin
Mehmet Mutlu Meydanli
Mustafa Erkan Sari
Ibrahim Yalcin
Gonca Çoban
Nazlı Topfedaisi Ozkan
Zeliha Firat Cuylan
Baki Erdem
Kemal Gungorduk
Özgür Akbayir
Murat Dede
Mustafa Coşkun Salman
Tayfun Güngör
Ali Ayhan
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2018
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-018-0393-0

Other articles of this Issue 1/2018

Journal of Ovarian Research 1/2018 Go to the issue